Research programme: synthetic antimicrobial and antibiofilm peptides - Madam Therapeutics
Latest Information Update: 21 Feb 2023
At a glance
- Originator Academic Medical Center; Leiden University Medical Center
- Class Antiacnes; Antibacterials; Drug conjugates; Foot disorder therapies; Peptide antibiotics; Skin disorder therapies
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acne vulgaris
- Research Bacterial infections; Diabetic foot ulcer
Most Recent Events
- 25 Jan 2023 Synthetic antimicrobial and antibiofilm peptides - Madam Therapeutics is available for licensing as of 25 Jan 2023. https://madamtherapeutics.com/ (Madam Therapeutics pipeline, January 2023).
- 23 Jan 2023 Madam Therapeutics in-licenses synthetic antimicrobial and antibiofilm peptides library from Academic Medical Center, Leiden University Medical Center (Madam Therapeutics website, January 2023)
- 23 Jan 2023 Early research in Bacterial infections in Netherlands (PO) prior to January 2023 (Madam Therapeutics pipeline, January 2023)